Post-market Control of Medical Device

Dr Terence CHEUNG
Medical Device Control Office
Department of Health





Post-market control

Post - market

Medical Device Safety Alert Surveillance System

➤ DH maintains vigilance on medical device safety alerts issued by overseas authorities and follow up as appropriate

Adverse Event (AE) Reporting

LRPs (and/or manufacturers) are required to report and investigate adverse events

Tracking of specified MDs

➤ Tracking of selected high-risk medical devices by LRPs and manufacturers, e.g. active cardiac implants





Post-market control – MD Safety Alert

Source of Information

- Website screening US FDA / Health Canada / UK MHRA /TGA / Singapore HSA
- National Competent Authority Report (NCAR)
- Traders (Suppliers or manufacturers)

Contact the local supplier/ manufacturer

- Request necessary information
 - Local distribution of the affected products
 - Relevant field safety notice
 - Root cause analysis and proposed corrective actions & preventive actions (CAPA)

Risk Assessment

Risk Communication

- E-mail notification to relevant stakeholders
- Web message
- Letter to Healthcare Professionals
- Press Release
- Summary of safety alerts

Follow-up Actions (where appropriate)

- Monitor the manufacturer's / local supplier's progress of actions
 - Notification of affected users
 - Root cause analysis
 - ☐ CAPA e.g. software upgrade, IFU update etc.

Actions taken by MDCO

- Contact the local supplier/ manufacturer and request the following information
 - Local distribution of the affected products
 - Relevant field safety notice
 - Root cause analysis and proposed corrective actions & preventive actions (CAPA)

- Risk assessment
- Risk communication





Risk communication

- Email notification to relevant stakeholders
- Web message
- Letter to Healthcare Professionals

Press Release

Summary of safety alerts





Summary of Safety Alerts



Major Safety Alerts in July 2013

Next: FDA = Food and Chig Administration, United States of Avenue, SMRN = Medicines and Healthcare products Registery Agency, United Ringston; Health Consts = 1900th Consts Consts.

CorrectMMs to	Colombition of Product	Nowon of information?	Statement Str. by Source	Arest Type by Bosensi	Lond Agent	Agent Contact Telephone No.
3613/67/62	Bester Dakreum UGA BD WAX nationwith (Calabopur in): 481916)	THE	RG-2015-RH-00083-2	Class F	Bertan Dokumon Asia Londad (RD):	25758688 EAT
2013/07/02	Stemans Dimension Visia SCC and Chromaton Visia 1993 using sufficient artistics 3.5.1 and 3.6 Sections III-SA Assign by use or homelies from the 1995 broader 2005 and	THE	MC-2013-MH-00049-1	Owelf	Diagnosis Limited	2916 76357 2879 7888
301340100	revealte 2000 NR prototen	THE	NC-2013-FRE-00040-1	Chee F	Sintegra Headhcare Diagnostic Condess	3870 7635 / 3875 7888
2513/67/62	Section Ply List fleet Blood Cell Arithmaty Identification Resignet - Phenocell C C. Phy. List res. (907)(872)	zus	HC-2013-RH-00K38-7	Clear III	NA.	HA.
261347782	Pyramed Pty Ltd Billary Presumppet Steric Bill 1809/99	Tite	RC-2013-RN-06615-1	Clean F	N.A.	NA.
381340182	B. Braur Motosi Ltd Comerdess Columbus Yorks System	THE	PC-2015-PH-00037-1	Class F	United Base (Hong) Kerse Util	NA.
2813/07/00	RD RD Plantask Stort Law Lak Syringe - TrenterProduct code: 800000;	10.014	2012/00/2012/00/2016	Filtre	90	2575 8999
381340190	Topose filio Talte	MARKE	28104004039284999	F94	NA.	16.6
2013/01/02	Totals TEKgel GE & That I'lls count on the Totals Automated Considering State Analysis Action 2018 Community on Child State Co. 1985(54) Let per Totals Vision State State on ESP 201 1885 2018 Vision State Child State Totals Vision State State on ESP 201 1885 2018 Vision State Child State 1 State Children State Child	MERSA	2010/00/04/40/0011	FSR	N.A.	NA:
281345792	Tracia Tracca basel (Santa ros: REP 301 - REP 300; Production date: 1 Dec 2012 to 15 Jun 2012)	SHIPA	2013/00000214881/896	FSN	N.A.	NA.
3813/67/02	Sriegra Calla CMF Brain Tideus Cinque and Tompendure Cultistar Nits	MEDA	2013/00/00/02/08/1/004	F1076	N.A.	NA.
361545402	Graffue Graffue Delivery Co.n. A1032, HUECTON, ARTHRES Demony Cur-	10.00	381900001-4291683	F1974	N.A.	N.A.
2513/5750	Held: B. Co., 813 HSCO-AGAIA THERMI 1913 (Swine) Hsc., 521327-121457;	MARIA	20190960122255885	F98.	N.A.	NA.
281349782	Warfer Group, Indicate tration Cabrothery 6,46 (60/00) analyzer specific to the use of 6, TEST MACRETIAM part no. 100:1570(140)	50.050	2010/00/USDW081/006	P194	World Hung Hang	2792 7779
361345762	Mark Cough V Factor C44, Lot co.: 211249. Every date: 21 Jan 2015.	MERCA	20130006/012801/884	FSM	N.A.	NA.
2019/07/02	Printed Sentil their Printed ins. 600-601 standard model; 606-701 rags model, 600-601-3500 absolute model, 600-701-3500 riset model.	MERCA	28190050022291081	FIDN	10.4.	Na.
26134782	Specialists Parallicans ATRICAL Aresthesia System	MARKET.	2012/00/07/2018 1/666	FSH	N.A.	NA.
2813/67/69	Meditorial traudit reservoirs (Model no. MMT-326A, MMT-335A)	Fare	Aug.	PAA:	Mediums Menudishal	28191362
2012/07/08	in the Testrologies Medicale Sour Pro-Clear Sponge NF (Catalogue in MED-MCS190), Best pp. F2-1378012 and F2-14881121	256	MC2013-MH-00213-1	Cleekit	NA.	NA.
2017/01/08	Handiser & V. Bie Contin Wheelter	MINA	MESCASSISSAU	MEA	N.A.	NA.
38154766	Elekia Al Digital Accelerators with Electrons and Boarn Mindulator, M. CAM.CC., Autily of Appropriate French.	196	MC-2015-MH-00MET-1	Clean	Street e 1200	29012338
261340786	Direct missel fluttings Delivery Guiden Alts (Catalogue running 2090/001), List Humberts A1201828, ACXIND16, A1208005, A11080000	Tile .	RG-2013-AN-00XIZ-1	Class F	Styker Chrostat	24 MH
38156768	Serving ADVIA Certain Newscriptons (PCV) Assay used with the ADVIA Certain, Certain VF, and Certain CF subserie	tue	MC-2013-MN-00872-1	Chee III	Degrada Lorded	2879/75257 2870/7888
20130705	Broad as A3 Plan 13 (Software viv) (Plan CMF 31, Plan Cranie 53, Plan SNF 13, Plan Plan 13, Plan Salm 13, Plan Shrepton 13, Plan Shrepton 13, Orașintra al	Fem	CAP4-20130927-66028	NA.	Stenius List	24171001
251345768	Coffine Connect Chappineston, Inc. 1/179/CD Cohemistry Products Nr. (Publishmen) Studen (Resignet), 1/179/CD Charlestry Products CRP Stone (Resignet) 1/9/CP Catalogue (m. 815-7586, 192 (CSE) and 835 (798).	čia.	2.1614.2013.ave2.1016.2013	Ownit	Johnson E. Adreson (Hong Kong) SIE	2758-1627
2013/07/06	Tectorio Cardinissimilia: Systema Corporation The Same TCM 3 Temperature Coreso Mostor Estatuque Sumine: 6410 8 Same no. 4635, 6007, 4005, 4001. 4420. 4420. 4420.	SBA	2,1999-2013	Clare E	TERUNO CHINA (PUK) 670.	2800011
28198759	Transco Patric Scientific Outre Antenocratic Scientific Facing Dec 16400 Terrosotto, C700000, Let (274010	MILETA.	2010/09/05/790/0002	F104	Thermo Pieter Scientific (1913)	2986 4615
2015/07/09	Therein Faller Spanish Could Administrate Succeptibility Teeting Day ARP IS Management C730008, Lot 1071623	Menta	2013007001401602	FIRM	Thems Paler Scientific (rth)	2889.4613






Last Revision Date : 26 AJy 2919

2512 B.; Privato Police | Impulsed Holices



Web message











Letter to Healthcare Professionals



香港特別行政區政府 衛生署 醫療機器管制辦公室

香港灣仔皇后大道東 183 號 合和中心 31 標 3101 室



THE GOVERNMENTOF THE HONG KONG SPECIAL ADMINISTRATIVE REGION DEPARTMENT OF HEALTH MEDICAL DEVICE CONTROL OFFICE

Boom 3101, 31/F., Hopewell Centre. 183 Onsen's Road East, Wan Chat. Hong Kong

丰貞種號 OUR REF: LM(t) to DHMDCO26-10-9

幸高權權 VOURBEE

31078484 THE 密铁 3157 1286 開空傳書 FAX:

18 January 2013

Dear Healthcare Professionals

United States Food and Drug Administration's safety recommendations on metal-on-metal hip implants

Further to our letter sent to you on 3 April 2012 on the safety concerns over metal-on-metal (MoM) hip implants (The letter is available website. http://www.mdco.gov.bk/english-emp/emp-hp/files-hcp-mom-pdf), your attention is drawn to the safety information and recommendations over MoM hip implants recently issued by the United States Food and Drug Administration (FDA)

In MoM hip implants, the metal ball and the metal cup slide against each other during mobilization causing some tiny metal particles to wear off of the device around the implant, and lead to damage to bone and/or soft tissue surrounding the implant and joint. Soft tissue damage may lead to pain, implant loosening, device failure and the need for revision surgery. Besides, some of the metal ions released may enter the bloodstream causing illnesses.

Based on its latest assessment of the issue, FDA has provided updated safety information and recommendations to patients and health care providers of MoM hip implants, including their benefits and risks, and the outcome of the June 2012 Orthopsedic and Rehabilitation Devices Advisory Panel meeting.

The safety communication provides recommendations for orthopaedic surgeons before the surgery and during patient follow-up, for imaging the implant, monitoring and assessing metal ion levels and considerations for device revision. Besides, recommendations are also given for patients considering hip implants, and those with metal-on-metal hip implants. FDA also advises all healthcare providers to watch out for metal ion adverse events that may occur in patients with MoM hip implant. These events may include general hypersensitivity reaction, cardiomyopathy, neurological changes including sensory changes, psychological status change, renal impairment and thyroid dysfunction. Patients with systemic findings should be advised to consult his or her orthopaedic surgeons for further actions.

竭減服務顧客係本素質损先

We are committed to providing client-oriented service







Press Release











Follow up actions

- Monitor the manufacturer's / local supplier's progress of actions
 - Notification of affected users
 - Root cause analysis
 - CAPA e.g. software upgrade, IFU update etc.





Post-market control – AE Reporting (1)

Objectives

To improve the **protection** of health and safety of patients, users and others by disseminating information that may **reduce** the likelihood of, or **prevent** repetition of adverse events associated with medical devices, or alleviated consequences of such repetition

Based on GHTF

Types of AE

- Death
- Serious Injury
- Serious public health concern
- Others





Post-market control – AE Reporting (2)

- Adverse Incidents to be <u>reported</u> under the MDACS
 - The LRP becomes **aware** of information regarding an incident that has occurred with his listed device(s)
 - The LRP's device is associated with the incident

The LRP's device is associated with the incident	
Outcomes	Reportable
Death of a patient, user or other person	YES
Serious injury of a patient, user or other person	YES
No death or serious injury occurred but the incident might lead to death or serious injury of a patient, user or other person of the incident recurs	YES

- Use errors meeting any of the following criteria
 ◆ Results in death or serious injury/serious public health concern
- ◆ A change in trend or a change in pattern of an issue that can potentially lead to death or serious injury or public health concern
- ◆When the LRP or manufacturer initiates corrective action to prevent death or serious injury or serious public health concern





YES

Post-market control – AE Reporting (3)

Source of Information

(LRP / MD supplier or manufacturer / Hospital or healthcare institution / Healthcare professionals, users & patients / Media)

AEs that results in

- Death
- Serious Injury
- Serious Public Health Concern

Report within 10 elapsed calendar days

All other reportable AEs

Report within 30 elapsed calendar days

Medical Device Control Office

Follow-up with the local supplier/ manufacturer

- Local and overseas incident statistics
- Investigation report with root cause analysis
- Proposed corrective actions and preventive actions (CAPA)

Actions taken When Necessary

- Request the local supplier / manufacturer to carry out field safety corrective actions, including recall
- On-site investigation
- Seek expert advice
- Press release





Thank you



Standard questions for safety alerts

- 1. Do you have any agencies in Hong Kong to represent you regarding the affected product?
- 2. Have this model (both affected and non-affected products) been distributed in Hong Kong? If affirmative, have the affected product been distributed in Hong Kong?
- 3. If you have supplied the affected products to Hong Kong, please provide us with the following information:
 - (a) The letter/information issued for the affected devices;
 - (b) The list of affected devices distributed in both the public and private healthcare service organizations in Hong Kong (such as public and private hospitals, clinics, health centres, laboratories, auxiliary medical service, etc.);
 - (c) Whether you have already notified all the affected organizations; and
 - (d) Your proposed rectification actions and programme, if any.





Standard questions for adverse incidents

To facilitate our investigation, we would be grateful if you could provide us with the following information:

- 1. Photo(s) of the broken device
- 2. Sales volume of _____
 - Local
 - Global
- No. of complaints/ incidents related to ______ in the same period of time
 - Local
 - Global
- 4. Root cause of the incident
- Relevant corrective and preventive actions, if applicable.

